PANTHER: Should Clopidogrel Become the 'New Aspirin' in CAD?

The PANTHER meta-analysis of trials comparing aspirin with clopidogrel or ticagrelor as antiplatelet monotherapy in coronary artery disease patients suggest that P2Y12 inhibitor therapy is more effective.

Related Keywords

Feldkirch ,Vorarlberg ,Austria ,Paris ,France General ,France ,Munich ,Bayern ,Germany ,Lugano ,Ticino ,Switzerland ,Spain ,Barcelona ,Comunidad Autonoma De Cataluna ,Heinz Drexel ,Marco Valgimigli ,Steffen Massberg ,Gabriel Steg ,European Society Of Cardiology ,University Hospital Munich ,Vorarlberg Institute For Vascular Investigation ,Cardiocentro Ticino Foundation ,European Society ,Medscape Cardiology ,Vorarlberg Institute ,Vascular Investigation ,Seen Despite Lack ,Cv ,Ardiovascular ,Atherosclerotic Heart Disease ,Therosclerotic Cardiovascular Disease ,Oronary Heart Disease ,Schemic Heart Disease ,Antiplatelet Agent ,Stroke Risk ,Myocardial Infarction ,Percutaneous Coronary Intervention ,